Last reviewed · How we verify
Antithyroid Drug — Competitive Intelligence Brief
phase 3
Antithyroid agent
Thyroid peroxidase (TPO)
Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Antithyroid Drug (Antithyroid Drug) — Seoul St. Mary's Hospital. Antithyroid drugs inhibit thyroid peroxidase and reduce thyroid hormone synthesis to treat hyperthyroidism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antithyroid Drug TARGET | Antithyroid Drug | Seoul St. Mary's Hospital | phase 3 | Antithyroid agent | Thyroid peroxidase (TPO) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antithyroid agent class)
- Seoul St. Mary's Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antithyroid Drug CI watch — RSS
- Antithyroid Drug CI watch — Atom
- Antithyroid Drug CI watch — JSON
- Antithyroid Drug alone — RSS
- Whole Antithyroid agent class — RSS
Cite this brief
Drug Landscape (2026). Antithyroid Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/antithyroid-drug. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing